The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today

Subscription options

Today, March 9, 2017, sees the start of the utilisation period of the series TO 1 subscription options issued in connection with SynAct Pharma AB’s (“SynAct”) issue in the spring of 2016 before the listing on Aktietorget. The utilisation period is ongoing until 23 March 2017. Holders of Series TO 1 subscription options have the right for each subscription options one to subscribe to one (1) new share in SynAct at a rate of SEK 6.40 per share. If all series TO 1 subscription options are utilised, approximately SEK 12.9 million before issue costs will be raised for SynAct. The proceeds obtained through current subscription options are intended to finance complementary research into other indications, in addition to the primary indication for the company’s candidate drug. Financing of the clinical development of the company’s candidate drug (Phase I and II studies) was secured through the issue the company conducted in May 2016 prior to listing on Aktietorget.

Investor meetings

In conjunction with the utilisation period of the subscription options, SynAct will participate in information meetings to give information about the Company’s activities and future plans. The information meetings are free to attend and light refreshments will be offered. For more information about investor meetings please visit Sedermera Fondkommission’s website (www.sedermera.se/investerartraffar) or contact Sedermera Fondkommission on telephone 040-615 14 10 or e-mail event@sedermera.se.

Date and time Organizer Address and City Application
10 March 2017, at 11.40am – 1.00pm Sedermera Fondkommission Scandic Klara, Slöjdgatan 7, Stockholm Fully Booked
14 March, 2017, at 8.00am – 8.30pm Aktiespararna Högskolan   för Lärande och Kommunikation, Gjutaregatan 5, Jönköping. http://www.aktiespararna.se

Summarized terms for series TO 1 subscription options

  •  Utilisation period: 9 – 23 March 2017 (by simultaneous cash payment no later than 3.00pm on 23 March 2017).
  •  Number of outstanding subscription options: 2 020 000 series TO 1 subscription options.
  •  Subscription value: The holder of subscription options has for each subscription option the right to subscribe to one (1) new share in SynAct at a rate of SEK 6.40 per share.
  •  Issue volume: With full utilisation of all warrants, SynAct will raise approximately SEK 12.9 million before issue costs of approximately SEK 0.5 million.
  •  Final Day of trading in subscription options: 21 March 2017.
  •  Valuation in current offer : Approximately SEK 78.5 million (pre-money).

Full terms and conditions for Series TO 1 subscription options, teaser and acceptance form warrants are available on the Synact website(www.synactpharma.se).. Teaser and application form are also available on Sedermera Fondkommission’s website (www.sedermera.se) and AktieTorget’s website (www.aktietorget.se).

Important dates related to the subscription options

  •  Utilisation period starts: 9 March 2017.
  •  Final Day of trading in subscription options: 21 March 2017.
  •  Utilisation period ends: 23 March 2017.
  •  Payment: Simultaneous cash payment no later than 15.00 on 23 March 2016.
  •  Planned communication of results: wk. 13 2017.
  •  Planned conversion of interim shares to shares : wk. 16 2017.

Note that the subscription options that are not sold by 21 March 2017, or used by 23 March 2017, will expire. To ensure that your subscription options do not expire, you are required to actively subscribe to shares or sell your subscription options.

How to use your series TO 1 subscription options

Do you have your subscription options in a deposit, in an investment savings account or in an endowment insurance (nominee-registered subscription options)?

In the event that the subscription options holder has its options in a holding, in an investment savings account or in a capital insurance (nominee-registered ownership), the subscription/payment shall be made to the relevant trustee, who gives further instructions regarding how to use the warrants. During the term of the subscription options, it is possible to convert from subscription options to shares during the period from 9 March to 23 March 2017. For more information and for further instructions regarding how to use your subscription options, please contact your trustee in good time. A folder containing a summary of terms and conditions for series TO 1 subscription options will be sent to all those who have their holdings nominee registered.

Do you have your subscription options in a VPC account (directly registered subscription options)?

No issue report will be sent out. However, the application form and folder containing summary of terms and conditions for series TO 1 subscription options have been sent out. The application form is also available at SynAct’s (www.synactpharma.se), Sedermera Fondkommission’s (www.sedermera.se) and Aktietorget’s (www.aktietorget.se) websites respectively.

When the application form is submitted to the Sedermera Fondkommission, payment must be made according to the payment instructions on the application form. During the term of the subscription options, conversion from subscription options to shares during the period from 9 March to 23 March 2017 is permitted, provided that the application form and settlement are subsequently received by the Sedermera Fondkommission by the date stated on the registration form. As soon as both subscription and payment have been registered with the Sedermera Fondkommission, the subscription options will be replaced by interim shares pending registration with the Swedish Company Registration Office. Thereafter, interim shares are replaced by shares.

For questions regarding series TO 1 subscription options, please contact:

Sedermera Fondkommission

Tel: 040-615 14 10

E-mail: info@sedermera.se

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                                  Henrik Stage

CEO, SynAct Pharma AB                                                                           CFO, SynAct Pharma AB

Telephone: +45 28 44 75 67                                                                    Telephone: +45 40 26 09 00
E-mail: joo@synactpharma.com                                                             E-mail: hs@synactpharma.com

This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 9 March 2016.